Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $8.00, but acceptable to hold if already in. Reasons: Market cap $0.82B below $1B minimum; Value-trap signals (3/5): High leverage (D/E 2.2), Material insider selling (55 sells, 0.73% of cap), Negative free cash flow.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as... Read more
Hold if already holding. Not a fresh buy at $8.00, but acceptable to hold if already in. Reasons: Market cap $0.82B below $1B minimum; Value-trap signals (3/5): High leverage (D/E 2.2), Material insider selling (55 sells, 0.73% of cap), Negative free cash flow. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Market cap $0.82B below $1B minimum. Not in investable universe. Score 4.8/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Oric Pharmaceuticals, Inc.
Latest news
- Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16 — benzinga May 5, 2026
- ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate — benzinga May 4, 2026
- ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeti — benzinga Apr 17, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 5.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.00, but acceptable to hold if already in. Reasons: Market cap $0.82B below $1B minimum; Value-trap signals (3/5): High leverage (D/E 2.2), Material insider selling (55 sells, 0.73% of cap), Negative free cash flow. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Market cap $0.82B below $1B minimum. Not in investable universe. Target $17.71 (+121.4%), stop $7.45 (−7.4%), A.R:R 10.4:1. Score 4.8/10, moderate confidence.
Take-profit target: $17.71 (+122.2% upside). Target $17.71 (+121.4%), stop $7.45 (−7.4%), A.R:R 10.4:1. Stop-loss: $7.45.
Market cap $0.82B below $1B minimum; Value-trap signals (3/5): High leverage (D/E 2.2), Material insider selling (55 sells, 0.73% of cap), Negative free cash flow.
Oric Pharmaceuticals, Inc. trades at a P/E of N/A (forward -5.1). TrendMatrix value score: 9.0/10. Verdict: Hold.
21 analysts cover ORIC with a consensus score of 4.3/5. Average price target: $20.
What does Oric Pharmaceuticals, Inc. do?ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of...
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.